Fitness

Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025

Triple-class exposed patients with three prior lines of therapy in CARTITUDE-1 and CARTITUDE-4 achieved a median PFS of 50.4 months...

Earlier use of CARVYKTI®▼ (ciltacabtagene autoleucel) demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma

Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression- and treatment-free following a single...

MENU – ORDER AI Announces Global Expansion with New Multilingual Capabilities, Supporting WHO Guidance on Dietary Needs for GLP-1 Users

New multilingual capabilities expand access to real-time GLP-1 dining guidance as WHO highlights the importance of protein-focused nutrition.BOSTON, Dec. 6,...

AIML Subsidiary NeuralCloud Enters Pilot with Cornerstone Physiotherapy to Deploy MaxYield(TM) and Insight360(TM) for Elite Athlete Cardiac Performance Testing

Early collaboration supports development of Cornerstone's emerging athlete-performance program and extends NeuralCloud's ECG analytics into sports-science and human performance marketsPilot...

error: Content is protected !!